Skip to Content

Verrica Pharmaceuticals Inc VRCA

Morningstar Rating
$5.92 +0.27 (4.78%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

VRCA is trading at a 44% discount.
Price
$5.03
Fair Value
$4.33
Uncertainty
Extreme
1-Star Price
$32.79
5-Star Price
$8.59
Economic Moat
Tjtjq
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if VRCA is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$5.65
Day Range
$5.606.03
52-Week Range
$2.867.76
Bid/Ask
$5.51 / $6.18
Market Cap
$251.12 Mil
Volume/Avg
92,024 / 165,828

Key Statistics

Price/Earnings (Normalized)
Price/Sales
52.39
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
100

Comparables

Valuation

Metric
VRCA
CRNX
IMVT
Price/Earnings (Normalized)
Price/Book Value
12.705.926.90
Price/Sales
52.39677.38
Price/Cash Flow
Price/Earnings
No chart available

Financial Strength

Metric
VRCA
CRNX
IMVT
Quick Ratio
4.3412.9221.56
Current Ratio
4.5513.0722.14
Interest Coverage
−16.60
Quick Ratio
VRCA
CRNX
IMVT

Profitability

Metric
VRCA
CRNX
IMVT
Return on Assets (Normalized)
−70.68%−38.81%−43.33%
Return on Equity (Normalized)
−112.62%−44.79%−47.83%
Return on Invested Capital (Normalized)
−77.30%−45.62%−52.69%
Return on Assets
VRCA
CRNX
IMVT
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRTzzljcyjrxQyr$570.1 Bil
VRTX
Vertex Pharmaceuticals IncLrhhctdgyQrwdwj$108.0 Bil
REGN
Regeneron Pharmaceuticals IncQzmnztkmBzfczd$105.6 Bil
MRNA
Moderna IncQytxzzzwrXfb$40.8 Bil
ARGX
argenx SE ADRPnxwrmtkKgfwp$23.5 Bil
BNTX
BioNTech SE ADRZfkhrfvTcbw$21.9 Bil
ALNY
Alnylam Pharmaceuticals IncPnsflqtyYbftlc$18.8 Bil
BMRN
Biomarin Pharmaceutical IncKplmytdyVvdyk$16.5 Bil
RPRX
Royalty Pharma PLC Class ASbtnbgxlwKxspj$13.6 Bil
INCY
Incyte CorpCpzgyrxfpTmpxmh$12.8 Bil

Sponsor Center